GlassScriptPhysician profile
Jigarkumar R Parikh
NPI 1073775722
$266,620.28
in general payments reported to CMS, 2019-2025
57 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53K · 2020: $14K · 2021: $18K · 2022: $46K · 2023: $71K · 2024: $40K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $80K · Consulting Fee: $30K · Travel and Lodging: $19K · Food and Beverage: $6,804 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $79,952.75 |
| Consulting Fee | $29,864.63 |
| Travel and Lodging | $18,607.48 |
| Food and Beverage | $6,803.69 |
| Education | $121.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $75,872.07 | 2019-2025 | Opdivo, Opdualag, Sprycel |
| Exelixis INC. | $68,446.73 | 2019-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $44,439.36 | 2022-2025 | |
| Pfizer INC. | $16,003.72 | 2021-2025 | |
| Astellas Pharma US INC | $15,621.73 | 2020-2025 | Padcev, Vyloy |
| Seagen INC. | $13,502.10 | 2020-2023 | Padcev, Tukysa |
| Astrazeneca Pharmaceuticals LP | $11,001.44 | 2020-2025 | Imfinzi, Calquence, Lynparza |
| Genzyme Corporation | $6,199.06 | 2022-2024 | |
| Celgene Corporation | $3,607.56 | 2021-2025 | Reblozyl, Pomalyst, Opdualag |
| Immunocore Limited | $2,000.00 | 2022 | |
| Daiichi Sankyo INC. | $1,527.57 | 2020-2025 | Vanflyta, Enhertu, Injectafer |
| Aveo Pharmaceuticals, INC. | $1,093.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $1,073.92 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Janssen Scientific Affairs, LLC | $1,010.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $753.99 | 2021-2025 |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $687.45 | 2022-2024 | Brukinsa |
| Janssen Biotech, INC. | $591.12 | 2020-2025 | Erleada, Balversa, Akeega |
| Amgen INC. | $316.42 | 2020-2023 | Lumakras |
| Eisai INC. | $284.65 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $268.98 | 2022-2023 | Ultomiris |
| Genentech USA, INC. | $261.17 | 2020-2025 | Polivy, Columvi, Lunsumio |
| Jazz Pharmaceuticals INC. | $198.81 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $191.60 | 2021-2024 | Libtayo |
| Puma Biotechnology, INC. | $174.06 | 2020-2024 | |
| Ipsen Biopharmaceuticals, INC | $163.57 | 2022-2024 | Onivyde, Somatuline Depot |
| Aroa Biosurgery Incorporated | $123.08 | 2022 | |
| Rigel Pharmaceuticals, INC. | $112.52 | 2021-2024 | Rezlidhia, Tavalisse |
| Array Biopharma INC | $111.72 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Abbvie INC. | $98.93 | 2021-2024 | |
| Coherus Oncology, INC. | $87.93 | 2022-2025 | Loqtorzi |
| Stemline Therapeutics INC. | $83.37 | 2023-2025 | Elzonris |
| Incyte Corporation | $74.18 | 2022-2025 | Jakafi |
| Glaxosmithkline, LLC. | $55.18 | 2024-2025 | Ojjaara, Zejula, Jemperli |
| Eusa Pharma (US) LLC | $45.96 | 2021 | |
| Taiho Oncology, INC. | $45.07 | 2023-2024 | |
| Epizyme, INC. | $42.77 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $42.72 | 2020-2023 | Imbruvica |
| Tesaro, INC. | $37.29 | 2019 | |
| Karyopharm Therapeutics INC. | $32.10 | 2020-2024 | Xpovio |
| Emd Serono, INC. | $30.35 | 2024-2025 | |
| Lilly USA, LLC | $29.66 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.48 | 2025 | Fruzaqla |
| Ferring Pharmaceuticals INC. | $26.13 | 2024 | Adstiladrin |
| Recordati_rare_diseases_inc. | $23.12 | 2023 | Sylvant |
| Acrotech Biopharma INC. | $21.74 | 2025 | Beleodaq |
| Adc Therapeutics America, INC. | $19.83 | 2024 | |
| Springworks Therapeutics, INC. | $19.08 | 2024 | Ogsiveo |
| Sumitomo Pharma America, INC. | $17.75 | 2025 | Orgovyx |
| Blueprint Medicines Corporation | $17.25 | 2020 | |
| Kite Pharma, INC. | $16.77 | 2021 | |
| Accord Healthcare, INC. | $15.93 | 2023 | |
| Sobi, INC | $15.63 | 2022 | |
| Gilead Sciences, INC. | $14.38 | 2022 | |
| Morphosys, US INC. | $14.11 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $13.13 | 2023 | |
| Pharmacosmos Therapeutics INC. | $12.84 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jigarkumar Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.